Mettler Toledo Launches New Liquid Handling Platform
PTSM: Pharmaceutical Technology Sourcing and Management
Mettler Toledo launched the Rainin BenchSmart 96, a new liquid handling platform.
On August 15, 2016, Mettler Toledo announced the launch of the Rainin BenchSmart 96, a new semi-automated 96-channel liquid handling platform. The BenchSmart is suitable for research, where experimental conditions change quickly and frequent modifications to the protocol are normal. BenchSmart's small footprint also makes it easy to move to wherever it is needed.
BenchSmart includes a large, touchscreen keypad and graphic interface. The platform improves the repeatability of experiments by eliminating variability in how liquids are aspirated and dispensed. BenchSmart gives users complete control over the instrument’s mechanical movement. Users can control the speed of the pipetting head, positioning tips within a plate or reservoir, and change the order of a protocol. The platform includes four tray positions and three interchangeable pipetting heads-0.5-20 µL, 5-200 µL, and 100-1000 µL. High-throughput tip options for the BenchSmart 96 include sterile, filter, and low retention, in both individual racks and convenient, space-saving stacks.
Source: Mettler Toledo
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
